Rom, Slava Zuluaga-Ramirez, Viviana Reichenbach, Nancy Dykstra, Holly Gajghate, Sachin Pacher, Pal Persidsky, Yuri Additional file 1: Figure S1. of PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier PARPi decrease PARP activity in a dose-dependent manner. PARP activity of primary monocytes treated with different concentrations of PARPi AIQ (A) and olaparib (B). Results are presented as the mean ± SEM (*P < 0.05, **P < 0.01 vs. untreated control) from two independent experiments for at least three replicates. Figure S2. PARP activity significantly diminished in ex vivo treated mouse leukocytes. (A) PARP activity was measured in freshly isolated and ex vivo PARPi-treated mouse leukocytes. Data are presented as mean ± SEM for at least three replicates from three/four donor mice. ***P < 0.005 indicate significance vs. non-treated. (B) Flow cytometry data presenting leukocyte profile of isolated leukocytes with or without PARPi treatment. Leukocyte-endothelial interaction;VLA-4;LFA-1;Actin cytoskeleton;PARP-1 2016-09-27
    https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Figure_S1_of_PARP_inhibition_in_leukocytes_diminishes_inflammation_via_effects_on_integrins_cytoskeleton_and_protects_the_blood-brain_barrier/4412744
10.6084/m9.figshare.c.3627311_D1.v1